Type 1 diabetes immunotherapy using polyclonal regulatory T cells (Q36509805)

14 August 2017

Type 1 diabetes immunotherapy using polyclonal regulatory T cells (English)

1 reference

14 August 2017

0 references

1 reference

7

Kevan C Herold

1 reference

14 August 2017

Jeffrey A Bluestone

1

1 reference

14 August 2017

Jane H Buckner

2

1 reference

14 August 2017

Mark Fitch

3

1 reference

14 August 2017

Stephen E Gitelman

4

1 reference

14 August 2017

Shipra Gupta

5

1 reference

14 August 2017

Marc K Hellerstein

6

1 reference

14 August 2017

Angela Lares

8

1 reference

14 August 2017

Michael R Lee

9

1 reference

14 August 2017

Kelvin Li

10

1 reference

14 August 2017

Weihong Liu

11

1 reference

14 August 2017

S Alice Long

12

1 reference

14 August 2017

Lisa M Masiello

13

1 reference

14 August 2017

Vinh Nguyen

14

1 reference

14 August 2017

Amy L Putnam

15

1 reference

14 August 2017

Mary Rieck

16

1 reference

14 August 2017

Peter H Sayre

17

1 reference

14 August 2017

Qizhi Tang

18

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 November 2015

1 reference

Science Translational Medicine

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

315ra189

1 reference

14 August 2017

315

1 reference

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

T cells in the control of organ-specific autoimmunity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

The therapeutic potential of regulatory T cells for the treatment of autoimmune disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Harnessing FOXP3+ regulatory T cells for transplantation tolerance.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Regulatory T-cell therapy in transplantation: moving to the clinic

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Standardizing immunophenotyping for the Human Immunology Project

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Genetics, pathogenesis and clinical interventions in type 1 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Expansion of human regulatory T-cells from patients with type 1 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Defective regulatory and effector T cell functions in patients with FOXP3 mutations.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729454

Regulatory T cells: stability revisited

21 September 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

Targeting memory T cells in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

Assessment of suppressive capacity by human regulatory T cells using a reproducible, bi-directional CFSE-based in vitro assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

Measurement of cell proliferation by heavy water labeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD4134

10.1126/SCITRANSLMED.AAD4134

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

1 reference